PAP Research and Registry Overview

Brenna Carey, MS, PhD
Assistant Professor
Translational Pulmonary Science Center
Cincinnati Children’s Hospital Medical Center
PAP Foundation Secretary/Treasurer
PAP Foundation Board Member
## Acknowledgements

<table>
<thead>
<tr>
<th>PAP Patients and Families</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CCHMC, Cincinnati, OH, USA</strong></td>
<td></td>
</tr>
<tr>
<td>Bruce Trapnell</td>
<td>(Marchele Bostic)</td>
</tr>
<tr>
<td>Claudia Chalk</td>
<td>(Colleen Fitzpatrick)</td>
</tr>
<tr>
<td>Jennifer Stock</td>
<td>(Greg Grabowski)</td>
</tr>
<tr>
<td>Paritha Arumugam</td>
<td>(Henry Greenberg)</td>
</tr>
<tr>
<td>Matt Wessendarp</td>
<td>(Maria Klingler)</td>
</tr>
<tr>
<td>Yan Ma</td>
<td>(Jon Puchalski)</td>
</tr>
<tr>
<td>Chris Towe</td>
<td>(Takuro Sakagami)</td>
</tr>
<tr>
<td>Jeff Whitsett</td>
<td>(Carrie Stevens)</td>
</tr>
<tr>
<td>Jason Woods</td>
<td>(Takuji Suzuki)</td>
</tr>
<tr>
<td>David Roach</td>
<td>(Andrea Toth)</td>
</tr>
<tr>
<td></td>
<td>(Kanji Uchida)</td>
</tr>
<tr>
<td></td>
<td>(Robert Wood)</td>
</tr>
<tr>
<td></td>
<td>(Susan Wert)</td>
</tr>
<tr>
<td><strong>UCLA, Ann Arbor, MI, USA</strong></td>
<td></td>
</tr>
<tr>
<td>Rachel Zemans</td>
<td></td>
</tr>
<tr>
<td><strong>UCLA, Los Angeles, CA, USA</strong></td>
<td></td>
</tr>
<tr>
<td>Tisha Wang</td>
<td>Elinor Lee</td>
</tr>
<tr>
<td>Liz Tarling</td>
<td>Carmela Granone</td>
</tr>
<tr>
<td>Cynthia Garcia</td>
<td></td>
</tr>
<tr>
<td><strong>University of Florida, Gainesville, FL, USA</strong></td>
<td></td>
</tr>
<tr>
<td>Ali Ataya</td>
<td></td>
</tr>
<tr>
<td><strong>U. of Niigata, Japan</strong></td>
<td></td>
</tr>
<tr>
<td>Koh Nakata, Ryushi Tazawa</td>
<td></td>
</tr>
<tr>
<td><strong>Kinki Chest Hosp., Japan</strong></td>
<td></td>
</tr>
<tr>
<td>Yoshikazu Inoue</td>
<td></td>
</tr>
<tr>
<td><strong>U. Pavia, Italy</strong></td>
<td></td>
</tr>
<tr>
<td>(Maruzio Luissetti), Ilaria Campo</td>
<td></td>
</tr>
<tr>
<td><strong>Ruhlandklinik, Germany</strong></td>
<td></td>
</tr>
<tr>
<td>Ulrich Costabel, Francesca Bonella</td>
<td></td>
</tr>
<tr>
<td><strong>NIH</strong></td>
<td></td>
</tr>
<tr>
<td>NHLBI - Lora Reineck, Louis Vuga, (Jerry Eu)</td>
<td></td>
</tr>
<tr>
<td>NCATS - Sharie Haugabook, (Holly Hamilton)</td>
<td></td>
</tr>
<tr>
<td><strong>Support</strong></td>
<td></td>
</tr>
<tr>
<td>Savara</td>
<td></td>
</tr>
<tr>
<td>Partner Therapeutics</td>
<td></td>
</tr>
<tr>
<td>NHLBI R01 HL085453</td>
<td></td>
</tr>
<tr>
<td>NHLBI R01 HL118342</td>
<td></td>
</tr>
<tr>
<td>Cincinnati Children’s Hospital</td>
<td></td>
</tr>
<tr>
<td>(NCATS/TRND Program)</td>
<td></td>
</tr>
<tr>
<td>(NCATS UL1 TR001425-0251)</td>
<td></td>
</tr>
<tr>
<td>(NCATS-NHLBI U54 HL127672)</td>
<td></td>
</tr>
<tr>
<td>(Genzyme - Leukine)</td>
<td></td>
</tr>
</tbody>
</table>
Outline

- Blood Tests to Diagnose PAP
- Clinical Course of Autoimmune PAP
- Utilization of Therapeutic Options for Autoimmune PAP
Outline

- Blood Tests to Diagnose PAP
- Clinical Course of Autoimmune PAP
- Utilization of Therapeutic Options for Autoimmune PAP
# Diseases Associated with PAP Syndrome

<table>
<thead>
<tr>
<th>Disease</th>
<th>Cause</th>
<th>Therapeutic approaches</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoimmune PAP (aPAP)</td>
<td>GM-CSF autoantibody (GMAb)</td>
<td>WLL, GM-CSF, Rituximab, Plasmapheresis, Statins</td>
</tr>
<tr>
<td>Hereditary PAP (hPAP)</td>
<td>Mutations: CSF2RA or CSF2RB</td>
<td>WLL, Bone Marrow Transplantation, Gene therapy, Pulmonary Macrophage Transplantation</td>
</tr>
<tr>
<td>Secondary PAP (sPAP)</td>
<td>Myelodysplasia, Inhaled particulates, others</td>
<td>WLL (+/-), Treat underlying disease</td>
</tr>
<tr>
<td>Disorders of Surfactant Production (DSP)</td>
<td>Mutations: SP-B, SP-C, ABCA3, TTF1</td>
<td>Lung Transplantation</td>
</tr>
</tbody>
</table>
PAP Diagnosis Study

- A clinical research study has been available to help with the diagnosis of autoimmune PAP since 2004

- Consent patients, ship samples to CCHMC, and test blood for:
  - GM-CSF autoantibody
  - GM-CSF signaling
Serum GM-CSF autoantibody levels are elevated in autoimmune PAP patients.
GM-CSF Signaling

GM-CSF signaling is impaired in autoimmune PAP patients.
PAP Diagnosis Study

- Samples received from US and Australia, Belgium, Brazil, Canada, Chile, Croatia, Czech Republic, France, Germany, Hungary, India, Ireland, Israel, Italy, Netherlands, New Zealand, Poland, Slovenia, South Africa, Spain, Sweden, Taiwan, Turkey, United Kingdom

- To date, we have evaluated ~1000 individuals:
  - 60% – GMAbpos, GM-CSF signalingneg (autoimmune PAP)

- GM-CSF autoantibody and GM-CSF signaling assays were transferred to Diagnostic Immunology Laboratory at CCHMC to be performed under CAP/CLIA guidelines
Translating PAP Testing Into the Clinic

TPSC PAPKit™

Pulmonary Alveolar Proteinosis Diagnostic Blood Spot Card Test Kit

• Easy to Use
• Convenient and Safe
• Simply Send by Mail
• Confidential

TPSC PAPKit™

Pulmonary Alveolar Proteinosis Diagnostic Blood Spot Card Test Kit

Instructions

Simple Fingerstick Blood Collection Kit for Identification of Diseases that Cause Pulmonary Alveolar Proteinosis
• Easy to Use
• Convenient and Safe
• Confidential
• Simply Send by Mail
• Free Test - All Costs Paid by the PAP Foundation and Rare Lung Diseases Consortium

To request additional TPSC PAPkits™, please call 1-513-636-6361.

Administered by

Translational Pulmonary Science Center Laboratory
Cincinnati Children’s Hospital Medical Center

Diagnose Blood Spot (BD) Card - FRONT

Read instructions on back before beginning.

Key: PAP = Pulmonary alveolar proteinosis

A. Medical History of Patient to be Tested
   - Has been diagnosed with PAP
   - A diagnosis of PAP is suspected
   - A family member has PAP
   - Has other lung disease
   - Has other non-lung disease
   - Is healthy — has no known chronic disease(s) or symptoms

B. Symptoms (Check all that apply)
   - None
   - Breathlessness
   - Cough
   - Fatigue
   - Fever
   - Sputum (Phlegm)
   - Other (describe)

C. Patient received and read brochure entitled: “TPSC PAPkit Instructions” and “What is Pulmonary Alveolar Proteinosis (PAP)? Should it be Tested?” Yes No

D. Blood Spot Information
   - Date blood was collected:

E. Patient Information
   - Date of Birth
   - Gender: Male Female
   - First Name:
   - Last Name:
   - Telephone:

F. Send results to physician listed below: Yes No

G. Physician Information
   - First Name:
   - Last Name:
   - Institution or Medical Center:
   - Street:
   - Suite:
   - City:
   - State:
   - Telephone:
   - Fax:

**PLEASE FILL OUT COMPLETELY**

This entire card must be completed for the sample to be processed.
GM-CSF autoantibody levels measured from dried blood spot cards are elevated in patients with autoimmune PAP.
Outline

- Blood Tests to Diagnose PAP
- Clinical Course of Autoimmune PAP
- Utilization of Therapeutic Options for Autoimmune PAP
What is Pulmonary Alveolar Proteinosis (PAP)?

Should I Be Tested?

We invite you to join the National Registry for pulmonary alveolar proteinosis (PAP), a joint program of the PAP Foundation and the Rare Lung Diseases Consortium. The purpose of the research database is to identify a group of people who are interested in receiving information about PAP and possibly participating in these research studies.

One hurdle to developing effective diagnostic tests and treatments for PAP has been that PAP occurs rarely—in about 7 out of every one million people. Further, PAP is not one disease but, rather, a syndrome that occurs in multiple diseases, which are even more rare and differ in their natural history, diagnosis, prognosis, and response to treatment. Finally, no routine clinical tests are available that doctors can use to identify the PAP-causing disease in most PAP patients.

Significant research advances have led to the development of accurate diagnostic tests and promising treatment approaches for autonomous PAP and other PAP-causing diseases. Clinical studies of these new potential treatments are being planned. Knowing which disease is causing PAP in a person is needed to understand their clinical course, prognosis, and for choosing appropriate therapy to treat the PAP-causing disease in that person.

The National PAP Registry is a part of a clinical research study designed to overcome these hurdles. By gathering medical information from enough people with PAP, we can improve our understanding about this rare syndrome. This study will also facilitate the evaluation of new tests to identify PAP-causing diseases. Finally, it will provide information about PAP and PAP research to patients and their families and doctors. We keep all personal information about participants in strictest confidence. More information about the study and how confidentially is kept can be found in the informed consent document. You can obtain additional information from the person in charge of this study, Dr. Bruce Trapnell, using the contact information provided at the end of the Questionnaire.

We designed the Registry Questionnaire to be quick and easy by writing short answers in the space provided to the right of each question. Some numbered questions are followed by one or more unnumbered questions that refer back to the immediately preceding numbered question. Extra space is provided in some sections to permit inclusion of further information, if needed. A parent (or legal guardian) may complete the questionnaire for a Participant who is a child or minor. To maximize the value of your contribution to this study, it is important to answer all questions. All questions refer to information about the Participant, except where indicated.

Definitions of selected key terms used in the Registry Questionnaire: The term ‘Participant’ is used to indicate the person with PAP who will be enrolled in the Registry. ‘You’ refers to the Participant who will be enrolled in the Registry. ‘Child’ refers to anyone less than 18 years of age at the time the questionnaire is completed. ‘Parent’ will be used to refer to either a parent or legal guardian of a minor Participant. ‘Symptom’ refers to a Participant experience, such as cough, pain, or breathing issues—a feeling of being unable to "take a good breath" or "get enough air." Definitions of other terms and more information about the National PAP Registry can be found in the brochure available from the PAP Foundation at their website located at www.PAPfoundation.org or the Rare Lung Diseases Consortium website located at www.rarelungdiseasesnetwork.org/ndl.

The National PAP Registry is a project developed jointly among and with support from the PAP Foundation, Rare Lung Diseases Consortium (RLDC), and Translational Pulmonary Sciences Center (TPSC). The RLDC is funded by the National Institutes of Health (NIH) (U54HL127872) and is a part of the National Center for Advancing Translational Science (NCATS) Rare Diseases Clinical Research Network (RD Crus). The RD Crus is an initiative of the Office of Rare Diseases Research (ORDR) and NCATS and is funded through a collaboration between NCATS and the National Heart, Lung and Blood Institute.
National PAP Registry participants are distributed across the United States.
National PAP Registry participants comprise both genders and multiple age groups.
Many PAP patients undergo transbronchial biopsy, surgical lung biopsy, or both even though neither is diagnostic for any PAP-causing disease.
Symptoms Reported Prior to Diagnosis

National PAP Registry participants most commonly report breathlessness, fatigue, and cough prior to diagnosis.
Outline

- Blood Tests to Diagnose PAP
- Clinical Course of Autoimmune PAP
- Utilization of Therapeutic Options for Autoimmune PAP
Utilization of Therapeutic Options for Autoimmune PAP

National PAP Registry participants most commonly report breathlessness, fatigue, and cough prior to diagnosis.
National PAP Registry participants report variation in the frequency of WLLs, ranging from 1 WLL to more than 5.
Summary

- Blood tests have been developed that are highly accurate for the diagnosis of autoimmune PAP.

- Many PAP patients undergo a lung biopsy which is not diagnostic for any PAP-causing disease. Lung biopsy should be reserved for difficult cases in which diagnosis remains unclear.

- Symptoms at presentation are non-specific and non-diagnostic. Breathlessness is the most common symptom reported by PAP patients.

- The majority of aPAP patients need therapy. The most common therapy is WLL which is required on a recurrent basis and the frequency was highly variable among individuals.
Future Research Questions

- How reliable is the new ‘blood droplet” test for the diagnosis of PAP?
- Are there better tests for diseases that cause PAP?
- What should be the criteria for a diagnosis of autoimmune PAP?
- What is the clinical course of autoimmune PAP over time?
- What are best indications for a whole lung lavage?
- What is the proper dose and administration frequency for GM-CSF therapy?
- How long will it take for patients to see improvement?
- The National PAP Registry is an opportunity for us to answer some of these questions.
- If you are interested in participating in the National PAP Registry, please contact me at email Brenna.Carey@cchmc.org.